Daniel Busby
Stock Analyst at RBC Capital
(1.16)
# 3,516
Out of 4,873 analysts
6
Total ratings
50%
Success rate
-8.02%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Daniel Busby
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VRCA Verrica Pharmaceuticals | Downgrades: Sector Perform | $16 → $4 | $0.60 | +568.90% | 2 | May 25, 2022 | |
| PFE Pfizer | Maintains: Sector Perform | $43 → $44 | $24.31 | +81.00% | 1 | Jun 17, 2021 | |
| MNKD MannKind | Initiates: Sector Perform | $5 | $3.99 | +25.31% | 2 | May 14, 2021 | |
| ABBV AbbVie | Reiterates: Outperform | $135 | $185.55 | -27.24% | 1 | May 3, 2021 |
Verrica Pharmaceuticals
May 25, 2022
Downgrades: Sector Perform
Price Target: $16 → $4
Current: $0.60
Upside: +568.90%
Pfizer
Jun 17, 2021
Maintains: Sector Perform
Price Target: $43 → $44
Current: $24.31
Upside: +81.00%
MannKind
May 14, 2021
Initiates: Sector Perform
Price Target: $5
Current: $3.99
Upside: +25.31%
AbbVie
May 3, 2021
Reiterates: Outperform
Price Target: $135
Current: $185.55
Upside: -27.24%